<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Icatibant: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Icatibant: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Icatibant: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="16808" href="/d/html/16808.html" rel="external">see "Icatibant: Drug information"</a> and <a class="drug drug_patient" data-topicid="16809" href="/d/html/16809.html" rel="external">see "Icatibant: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F13206139"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Firazyr;</li>
<li>Sajazir</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871383"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Firazyr</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F15387128"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Selective Bradykinin B2 Receptor Antagonist</span></li></ul></div>
<div class="block dop drugH1Div" id="F53390433"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c8537c74-aa3e-46c0-8362-8945e4a603be">Hereditary angioedema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema (HAE):</b> Limited data available: Children ≥2 years and Adolescents: SubQ: 0.4 mg/kg once; maximum dose: 30 mg/dose. Dosing based on an open-label study of 32 patients (mean age: 12.3 ± 3.5 years) with HAE (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28601641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28601641'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F53390435"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; however, icatibant is cleared by nonrenal mechanisms and is not expected to accumulate in patients with renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F53390436"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; however, based on adult experience, no change in systemic exposure was observed in patients with mild to moderate hepatic impairment.</p></div>
<div class="block doa drugH1Div" id="F13206200"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="16808" href="/d/html/16808.html" rel="external">see "Icatibant: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e6fdac7f-1466-435d-8ceb-b7b28141de63">Hereditary angioedema attacks, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary angioedema attacks, treatment:</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>To minimize morbidity and mortality, should be self-administered (or administered by a caregiver) at the onset of an attack whenever possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32898710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32898710'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 30 mg once; may repeat every 6 hours if response is inadequate or symptoms recur; maximum dose: 90 mg per 24 hours.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991870"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment is recommended (has not been studied); icatibant is cleared by nonrenal mechanisms and is not expected to accumulate in patients with renal impairment.</p></div>
<div class="block doha drugH1Div" id="F50989177"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block adr drugH1Div" id="F13206164"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Local: Injection site reaction (97%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminase (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (4%; anti-icatibant, no association with efficacy observed)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Dermatologic: Urticaria</p></div>
<div class="block coi drugH1Div" id="F13206161"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in US labeling): Hypersensitivity to icatibant acetate or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F13206162"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Airway obstruction: Airway obstruction may occur during acute laryngeal attacks of HAE. Patients with laryngeal attacks should be instructed to seek medical attention immediately in addition to treatment with icatibant.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F53390431"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Airway obstruction may occur during acute laryngeal attacks of HAE; due to smaller airway passages, this may occur more rapidly in pediatric patients. Patients with laryngeal attacks should seek medical attention immediately following icatibant administration.</p></div>
<div class="block foc drugH1Div" id="F13206140"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous, as acetate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Firazyr: 30 mg/3 mL (3 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sajazir: 30 mg/3 mL (3 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg/3 mL (3 mL)</p></div>
<div class="block geq drugH1Div" id="F20452816"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322916"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Firazyr Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/3 mL (per mL): $4,459.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Icatibant Acetate Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/3 mL (per mL): $560.00 - $4,236.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Sajazir Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/3 mL (per mL): $4,000.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871384"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Firazyr: 30 mg/3 mL (3 mL)</p></div>
<div class="block admp drugH1Div" id="F53390437"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">SubQ: For SubQ administration only. For doses &lt;30 mg, transfer the appropriate volume needed for dose from the prefilled syringe into a graduated syringe. Inject into the abdomen over ≥30 seconds. Inject 2 to 4 inches below belly button and at least 2 inches away from any scars; do not inject into an area that is bruised, swollen, or painful.</p></div>
<div class="block adm drugH1Div" id="F13206204"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">SubQ: For SubQ injection only. Patients may self-administer upon recognition of an HAE attack. Inject into the abdomen over ≥30 seconds, using the 25 gauge needle provided. Inject 2 to 4 inches below belly button and away from any scars; do not inject into an area that is bruised, swollen, or painful.</p></div>
<div class="block hazard drugH1Div" id="F49132619"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F13206179"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store between 2°C to 25°C (36°F to 77°F); do not freeze. Store in original container until time of administration.</p></div>
<div class="block usep drugH1Div" id="F53570971"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of acute attacks of hereditary angioedema (HAE) (FDA approved in adults).</p></div>
<div class="block cyt drugH1Div" id="F13299506"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F13225901"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Icatibant may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13206159"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data following maternal administration of icatibant for the treatment of hereditary angioedema (HAE) attacks during pregnancy are limited (Boufleur 2014; Farkas 2016; Hakl 2018; Kaminsky 2017; Tran 2013; Zanichelli 2015).</p>
<p style="text-indent:0em;margin-top:2em;">When treatment for acute attacks of hereditary angioedema in pregnancy is needed, agents other than icatibant are recommended. Patients with HAE should be monitored closely during pregnancy and for at least 72 hours after delivery (Betschel 2019; WAO/EAACI [Maurer 2022]).</p></div>
<div class="block mopp drugH1Div" id="F53570970"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Symptom relief; laryngeal symptoms or airway obstruction (immediate medical attention required in addition to icatibant therapy); reproductive hormones in pediatric patients receiving frequent dosing.</p></div>
<div class="block pha drugH1Div" id="F13206180"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Icatibant is a selective competitive antagonist for the bradykinin B<sub>2</sub> receptor. Patients with HAE have an absence or dysfunction of C1-esterase-inhibitor which leads to the production of bradykinin. The presence of bradykinin may cause symptoms of localized swelling, inflammation, and pain. Icatibant inhibits bradykinin from binding at the B<sub>2</sub> receptor, thereby treating the symptoms associated with acute attack.</p></div>
<div class="block phk drugH1Div" id="F13206182"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Median time to 50% decrease of symptoms: ~2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Inhibits symptoms caused by bradykinin for ~6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years: 0.39 ± 0.11 L/kg (Farkas 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: 0.44 ± 0.18 L/kg (Farkas 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 29 ± 8.7 L</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized by proteolytic enzymes to metabolites (inactive)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~97%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years: 0.8 ± 0.04 hours (Farkas 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: 1.34 ± 0.96 hours (Farkas 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 1.4 ± 0.4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years: 0.42 ± 0.13 hours (Farkas 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: 0.55 ± 0.19 hours (Farkas 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~0.75 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;10% unchanged)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F13276714"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant accord | Icatibant ratiopharm</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cipla icatibant | Firazyr | Fyzant</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant | Icatibant fresenius</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant xiromed</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant accord | Icatibant fresenius | Icatibant teva</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant accord | Icatibant axiromed | Icatibant cipla | Icatibant glenmark | Icatibant stada | Icatibant zentiva</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant accord | Icatibant teva</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant accord | Icatibanto cipla | Icatibanto glenmark | Icatibanto gp-pharm | Icatibanto stada</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatiban accord | Icatibant accord | Icatibant avansor | Icatibant glenmark | Icatibant ratiopharm | Icatibant sandoz | Icatibant stada | Icatibant zentiva</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant accord | Icatibant fresenius | Icatibant viatris | Icatibant zentiva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Icatibant accord</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant accord | Icatibant fresenius | Icatibant stada | Icatibant teva</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant accord</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant accord | Icatibant eg | Icatibant piramal | Icatibant teva | Icatibant zentiva</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Icatibant teva</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant accord | Icatibant fresenius | Icatibant teva | Icatibant viatris | Icatibant xiromed</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant | Icatibant glenmark | Icatibant newbury</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant accord</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant accord | Icatibant fresenius</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant stada | Icatibant zentiva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Firazir | Icatibant psk</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant accord | Icatibant avansor | Icatibant glenmark | Icatibant medical valley | Icatibant newbury | Icatibant sandoz | Icatibant stada | Icatibant teva | Icatibant zentiva</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Firazyr | Icatibant glenmark | Icatibant zentiva</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Bradikant | Estereban | Heact | Icatin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Firazyr</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24565614">
<a name="24565614"></a>Baram M, Kommuri A, Sellers SA, Cohn JR. ACE inhibitor-induced angioedema. <i>J Allergy Clin Immunol Pract</i>. 2013;1(5):442-445. doi:10.1016/j.jaip.2013.07.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/24565614/pubmed" id="24565614" target="_blank">24565614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25629740">
<a name="25629740"></a>Baş M, Greve J, Stelter K, et al. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. <i>N Engl J Med</i>. 2015;372(5):418-425. doi:10.1056/NEJMoa1312524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/25629740/pubmed" id="25629740" target="_blank">25629740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31788005">
<a name="31788005"></a>Betschel S, Badiou J, Binkley K, et al. The international/Canadian hereditary angioedema guideline. <i>Allergy Asthma Clin Immunol</i>. 2019;15:72. doi:10.1186/s13223-019-0376-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/31788005/pubmed" id="31788005" target="_blank">31788005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Boufleur.1">
<a name="Boufleur.1"></a>Boufleur K, Delcaro L, Cordeiro DL, et al. Successful and safe use of icatibant for life-threatening angioedema attack during pregnancy in a patient with hereditary angioedema type I. Abstracts of the 2014 AAAAI Annual Meeting, February 28-March 4, 2014, San Diego, CA. <i>J Allergy Clin Immunol</i>. 2014;133(2 suppl):AB36. doi:10.1016/j.jaci.2013.12.153</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32898710">
<a name="32898710"></a>Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema.<i> J Allergy Clin Immunol Pract</i>. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/32898710/pubmed" id="32898710" target="_blank">32898710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818888">
<a name="20818888"></a>Cicardi M, Banerji A, Bracho F, et al. Icatibant, A New Bradykinin-Receptor Antagonist in Hereditary Angioedema. <i>N Engl J Med</i>. 2010;363(6):532-541.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/20818888/pubmed" id="20818888" target="_blank">20818888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23282420">
<a name="23282420"></a>Craig T, Aygören-Pürsün E, Bork K, et al. WAO guideline for the management of hereditary angioedema. <i>World Allergy Organ J</i>. 2012;5(12):182-199. doi:10.1097/WOX.0b013e318279affa<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/23282420/pubmed" id="23282420" target="_blank">23282420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27093898">
<a name="27093898"></a>Farkas H, Kőhalmi KV, Veszeli N, et al. First report of icatibant treatment in a pregnant patient with hereditary angioedema. <i>J Obstet Gynaecol Res</i>. 2016;42(8):1026-1028. doi:10.1111/jog.13003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/27093898/pubmed" id="27093898" target="_blank">27093898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28601641">
<a name="28601641"></a>Farkas H, Reshef A, Aberer W, et al. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. <i>J Allergy Clin Immunol Pract</i>. 2017;5(6):1671-1678. doi:10.1016/j.jaip.2017.04.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/28601641/pubmed" id="28601641" target="_blank">28601641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Firazyr.1">
<a name="Firazyr.1"></a>Firazyr (icatibant) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Firazyr.2">
<a name="Firazyr.2"></a>Firazyr (icatibant) [product monograph]. Toronto, Ontario, Canada: Takeda Canada Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30280305">
<a name="30280305"></a>Hakl R, Kuklínek P, Krčmová I, et al. Treatment of hereditary angioedema attacks with icatibant and recombinant C1 inhibitor during pregnancy. <i>J Clin Immunol</i>. 2018;38(7):810-815. doi:10.1007/s10875-018-0553-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/30280305/pubmed" id="30280305" target="_blank">30280305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30365440">
<a name="30365440"></a>Hirschy R, Shah T, Davis T, Rech MA. Treatment of life-threatening ACE-inhibitor-induced angioedema. <i>Adv Emerg Nurs J</i>. 2018;40(4):267-277.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/30365440/pubmed" id="30365440" target="_blank">30365440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29070276">
<a name="29070276"></a>Kaminsky LW, Kelbel T, Ansary F, et al. Multiple doses of icatibant used during pregnancy. <i>Allergy Rhinol (Providence)</i>. 2017;8(3):178-181. doi:10.2500/ar.2017.8.0210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/29070276/pubmed" id="29070276" target="_blank">29070276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35497649">
<a name="35497649"></a>Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update.<i> World Allergy Organ J</i>. 2022;15(3):100627. doi:10.1016/j.waojou.2022.100627<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/35497649/pubmed" id="35497649" target="_blank">35497649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28552382">
<a name="28552382"></a>Sinert R, Levy P, Bernstein JA, et al; CAMEO Study Group. Randomized trial of icatibant for angiotensin-converting enzyme inhibitor-induced upper airway angioedema. <i>J Allergy Clin Immunol Pract</i>. 2017;5(5):1402-1409. doi:10.1016/j.jaip.2017.03.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/28552382/pubmed" id="28552382" target="_blank">28552382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27913306">
<a name="27913306"></a>Straka BT, Ramirez CE, Byrd JB, et al. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. <i>J Allergy Clin Immunol</i>. 2017;140(1):242-248. doi:10.1016/j.jaci.2016.09.051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/27913306/pubmed" id="27913306" target="_blank">27913306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24237653">
<a name="24237653"></a>Tran YD, de Malmanche T. Management dilemmas in a case of angioedema with normal C1 inhibitor function during pregnancy. <i>Intern Med J</i>. 2013;43(11):1259. doi:10.1111/imj.12281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/24237653/pubmed" id="24237653" target="_blank">24237653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed September 29, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26817146">
<a name="26817146"></a>Zanichelli A, Mansi M, Periti G. Icatibant exposure during pregnancy in a patient with hereditary angioedema. <i>J Investig Allergol Clin Immunol</i>. 2015;25(6):447-449.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icatibant-pediatric-drug-information/abstract-text/26817146/pubmed" id="26817146" target="_blank">26817146</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 121953 Version 119.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
